Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
FDA Clears Zanidatamab Phase 3 Pivotal Trial in First Line HER2-positive Gastroesophageal Adenocarcinoma
Zymeworks Reports 2021 First Quarter Financial Results
Zymeworks to Present at Bloom Burton Healthcare Conference
Zymeworks Introduces Fourth Therapeutic Platform, ProTECT™
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting
Congratulations to Zymeworks Scientist Anna von Rossum, Healthcare Business Women’s Association 2021 Rising Star!
Zymeworks is Proud of Two National Top Employer Recognitions Received in Canada, and Even Prouder of Our People Who Make Zymeworks Such a Great Place to Work!
